Next Article in Journal
Oncolytic Viruses for Multiple Myeloma Therapy
Next Article in Special Issue
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
Previous Article in Journal
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development
Previous Article in Special Issue
Frequency of EBV LMP-1 Promoter and Coding Variations in Burkitt Lymphoma Samples in Africa and South America and Peripheral Blood in Uganda
Commentary

Antiviral Drugs for EBV

1
Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3
Department of Microbiology and Immunology, University of Leuven, BE-3000 Leuven, Belgium
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(6), 197; https://doi.org/10.3390/cancers10060197
Received: 9 May 2018 / Revised: 7 June 2018 / Accepted: 12 June 2018 / Published: 13 June 2018
(This article belongs to the Special Issue Epstein–Barr Virus Associated Cancers)
Epstein–Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35–50% cases when infection occurs during adolescence and early adulthood. Epstein–Barr virus is also associated with several B-cell malignancies including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease. A number of antiviral drugs have proven to be effective inhibitors of EBV replication, yet have resulted in limited success clinically, and none of them has been approved for treatment of EBV infections. View Full-Text
Keywords: Epstein–Barr virus; maribavir; antiviral; acyclovir; ganciclovir Epstein–Barr virus; maribavir; antiviral; acyclovir; ganciclovir
MDPI and ACS Style

Pagano, J.S.; Whitehurst, C.B.; Andrei, G. Antiviral Drugs for EBV. Cancers 2018, 10, 197. https://doi.org/10.3390/cancers10060197

AMA Style

Pagano JS, Whitehurst CB, Andrei G. Antiviral Drugs for EBV. Cancers. 2018; 10(6):197. https://doi.org/10.3390/cancers10060197

Chicago/Turabian Style

Pagano, Joseph S., Christopher B. Whitehurst, and Graciela Andrei. 2018. "Antiviral Drugs for EBV" Cancers 10, no. 6: 197. https://doi.org/10.3390/cancers10060197

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop